General Information of Drug Transporter (DT)
DT ID DTD0019 Transporter Info
Gene Name SLC10A1
Transporter Name Sodium/taurocholate cotransporting polypeptide
Gene ID
6554
UniProt ID
Q14973
Post-Translational Modification of This DT
Overview of SLC10A1 Modification Sites with Functional and Structural Information
Sequence
PTM type
X-Dephosphorylation X-N-glycosylation X-Phosphorylation X-S-nitrosylation X: Amino Acid

Dephosphorylation

  Serine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Increasing in taurocholate uptake and SLC10A1 retention in the plasma membrane [1]

Role of PTM

Protein Activity Modulation

Affected Drug/Substrate

Taurocholate

Results for Drug

Incerasing uptake of taurocholate

Modified Residue

Serine

Modified Location

226

Related Enzyme

Protein phosphatase 3 catalytic subunit alpha (PPP3CA)

Studied Phenotype

Liver cancer [ICD11: 2C12]

Experimental Material(s)

Human hepatoma (HuH-7) cells

Experimental Method

Co-Immunoprecipitation

Detailed Description

Dephosphorylation at SLC10A1 Serine 226 have been reported to increase in taurocholate uptake and NTCP retention in the plasma membrane.

N-glycosylation

  Asparagine

          4 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Affecting the function of the physiological bile acid SLC10A1 [2]

Role of PTM

Protein Activity Modulation

Affected Drug/Substrate

Bile acids

Results for Drug

Affecting the transport of bile acids

Modified Residue

Asparagine

Modified Location

5

Modified State

Asparagine to Glutamine mutation

Studied Phenotype

Liver cancer [ICD11: 2C12]

Experimental Material(s)

Human liver carcinoma (HepG11) cells

Experimental Method

Co-Immunoprecipitation

Detailed Description

Removal of the N-glycosylation at SLC10A1 Asparagine5 (i.e. Asparagine to Glutamine mutation) have been reported to affect its function of the physiological bile acid transporter.

  PTM Phenomenon 2

Affecting the function of the physiological bile acid SLC10A1 [2]

Role of PTM

Protein Activity Modulation

Affected Drug/Substrate

Bile acids

Results for Drug

Affecting the transport of bile acids

Modified Residue

Asparagine

Modified Location

11

Modified State

Asparagine to Glutamine mutation

Studied Phenotype

Liver cancer [ICD11: 2C12]

Experimental Material(s)

Human liver carcinoma (HepG11) cells

Experimental Method

Co-Immunoprecipitation

Detailed Description

Removal of the N-glycosylation at SLC10A1 Asparagine11 (i.e. Asparagine to Glutamine mutation) have been reported to affect its function of the physiological bile acid transporter.

  PTM Phenomenon 3

Have the potential to influence SLC10A1 [3]

Role of PTM

Potential impacts

Modified Residue

Asparagine

Modified Location

117

Experimental Method

Co-Immunoprecipitation

Detailed Description

N-linked Glycosylation at SLC10A1 Asparagine 117 has the potential to affect its expression or activity.

  PTM Phenomenon 4

Have the potential to influence SLC10A1 [3]

Role of PTM

Potential impacts

Modified Residue

Asparagine

Modified Location

336

Experimental Method

Co-Immunoprecipitation

Detailed Description

N-linked Glycosylation at SLC10A1 Asparagine 336 has the potential to affect its expression or activity.

Phosphorylation

  Serine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLC10A1 [4]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

142

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLC10A1 Serine 142 has the potential to affect its expression or activity.

S-nitrosylation

  Cysteine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

May contribute to the development of cholestasis by inhibiting SLC10A1 function [5]

Role of PTM

Protein Activity Modulation

Affected Drug/Substrate

Na(+) taurocholate (TC)

Results for Drug

Decreasing uptake of Na(+) taurocholate (TC)

Modified Residue

Cysteine

Modified Location

96

Studied Phenotype

Liver cancer [ICD11: 2C12]

Experimental Material(s)

Human hepatoma (HuH-7) cells

Experimental Method

Co-Immunoprecipitation

Detailed Description

S-nitrosylation at SLC10A1 Cysteine 96 have been reported to potentially inhibit its function and thus contribute to the development of cholestasis.
References
1 Dephosphorylation of Ser-226 facilitates plasma membrane retention of Ntcp. J Biol Chem. 2005 Sep 30;280(39):33687-92.
2 N-Glycosylation of the Na+-Taurocholate Cotransporting Polypeptide (NTCP) Determines Its Trafficking and Stability and Is Required for Hepatitis B Virus Infection. PLoS One. 2017 Jan 26;12(1):e0170419.
3 dbPTM in 2022: an updated database for exploring regulatory networks and functional associations of protein post-translational modifications. Nucleic Acids Res. 2022 Jan 7;50(D1):D471-D479. (ID: NTCP_HUMAN)
4 Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014 Jul;13(7):1690-704.
5 Cysteine 96 of Ntcp is responsible for NO-mediated inhibition of taurocholate uptake. Am J Physiol Gastrointest Liver Physiol. 2013 Oct 1;305(7):G513-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.